Relief from lupus pain can be seen as a placeholder, not unlike that moment before a great discovery, writes columnist Candace Semien.

ADI-001 led to reductions in disease activity for seven lupus patients in a clinical trial, with no serious side effects reported, data show.

Telitacicept, a B-cell-targeting therapy developed by RemeGen, outperformed a placebo at reducing the severity of systemic lupus erythematosus (SLE) in a Phase 3 clinical trial in China, the company ...

Ventus Therapeutics plans to develop a new treatment candidate for lupus and other inflammatory diseases marked by the activation of the type 1 interferon immune system pathway, the company recently ...

Few couples hearing the term “in sickness and in health” at their wedding have thoughts of chronic illness enter their mind. But the reality is, with almost half of the American population dealing ...

The U.S. Food and Drug Administration (FDA) has cleared Century Therapeutics to start a Phase 1 clinical trial that will test its off-the-shelf cell therapy CNTY-101 in people with systemic lupus ...

Seattle Children’s has been cleared by the U.S. Food and Drug Administration (FDA) to start the nation’s first clinical trial testing CAR T-cell therapy in children with systemic lupus erythematosus, ...

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to FT819, a cell therapy Fate Therapeutics is developing to treat lupus. An RMAT ...

Let’s start with a little story, shall we? It’s currently 142 F outside. OK, that might be a slight exaggeration, but not by much. I’m living through one of the most brutal heat waves my area has seen ...

The Lupus Research Alliance and its affiliate, Lupus Therapeutics, have partnered with Takeda Pharmaceutical to conduct a Phase 1 clinical trial testing Takeda’s investigational antibody TAK-079 for ...

An associate professor of biomedical engineering at the University of Houston is developing a new way to deliver treatments for lupus directly to the spleen, which is the home of certain immune cells ...

Lupuzor (rigerimod, or IPP-201101) combined with standard therapy did not demonstrate a statistically significant response rate in systemic lupus erythematosus (SLE) patients over standard care alone, ...